A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
NCT ID: NCT01126424
Last Updated: 2012-10-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
26 participants
INTERVENTIONAL
2010-04-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Solifenacin
Participants received 21 days of treatment with 5 mg solifenacin, in tablet form once a day.
Solifenacin
tablet
Oxybutynin
Participants received 21 days of treatment with 10 mg oxybutynin (1 x 5 mg twice daily) in capsule form.
Oxybutynin
capsule
Placebo
Participants received 21 days of treatment with placebo.
Placebo
tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Solifenacin
tablet
Oxybutynin
capsule
Placebo
tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject conforms to the Stockholm criteria for mild cognitive impairment as assessed by the investigator
* The subject has a body mass index (BMI) between 18.0 to 30.0 kg/m2 inclusive
* The subject is available to complete the study
Exclusion Criteria
* The subject has depression as determined by Geriatric Depression Scale (GDS) short form ≥ 5 at screening
* The subject has a history of urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony or toxic megacolon or severe ulcerative colitis), myasthenia gravis, uncontrolled narrow angle glaucoma or shallow anterior chamber or deemed to be at risk for these conditions
* The subject is undergoing hemodialysis or has severe renal impairment or moderate hepatic impairment and who are on treatment with a potent CYP3A4 inhibitor, e.g. Ketoconazole
* The subject has uncontrolled diabetes mellitus
* The subject has a positive pre-study hepatitis B surface antigen, hepatitis C antibody or HIV result at time of screening
* The subject has a history of drug and / or alcohol abuse at time of screening
* The subject has an average weekly alcohol intake of greater than 21 units (male) or 14 units (female) within ≤ 3 months prior to screening (1 unit is 270cc of beer, 40cc of spirits or 125cc of wine)
* The subject has a history of smoking more than 10 cigarettes (or the equivalent amount of tobacco) per day within ≤ 3 months prior to screening
* The subject has a history of known or suspected hypersensitivity to solifenacin succinate, oxybutynin hydrochloride, other anti-cholinergics or lactose, to any component of the dosage form
* The subject has taken any unstable doses of prescribed medication within ≤ 1 month prior to screening or over-the-counter medicine (including vitamins and herbal remedies) within 48 hours prior to the first study day, which in the opinion of the Investigator, will interfere with the study procedures or compromise safety
* The subject is currently dosing with medication(s) intended to treat overactive bladder symptoms or has history of non-drug treatment intended to treat overactive bladder symptoms within ≤ 3 months prior to screening
* The subject has any clinically significant abnormality following Investigator review of the physical examination
* The subject has any clinically significant abnormality following the Investigator's review of the ECG
* The subject has mobility impairment that precludes the assessment of postural stability
* The subject has any clinically significant abnormal heart rate or blood pressure measurements, at the screening visit (dBP \> 90mmHg, sBP \> 160mmHg or HR \< 40bpm or \> 100bpm)
* The subject has any clinically significant abnormality following Investigator's review of the biochemistry \& hematology results which, in the opinion of the Investigator, contraindicates their participation
* The subject has donated blood or plasma within ≤ 3 months prior to screening or more than 500ml or 1 unit of blood or plasma within ≤ 6 months prior to screening
* The subject, may find it difficult to adhere to the provisions of treatment and observation specified in the protocol
* The subject has participated in any clinical study within ≤ 3 months prior to screening
* The subject has any clinical condition, diagnosis, symptomatology or ongoing investigation, which, contraindicates their participation
* The subject is an employee of Astellas Pharma, Cognitive Drug Research, and any other third party related to the study site
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Use Central Contact
Role: STUDY_DIRECTOR
Astellas Pharma Europe Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Blackpool, Lancashire, United Kingdom
Manchester, Lancashire, United Kingdom
Bradford, Yorkshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wright BM. A simple mechanical ataxia-meter. J Physiol. 1971 Oct;218 Suppl:27P-28P. No abstract available.
Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013 Jul;64(1):74-81. doi: 10.1016/j.eururo.2013.01.002. Epub 2013 Jan 11.
Related Links
Access external resources that provide additional context or updates about the study.
Link to Prescribing Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-005966-29
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
905-EC-008
Identifier Type: -
Identifier Source: org_study_id